Drug interactions
Idecabtagene vicleucel + Secukinumab
Severity: Moderate
Idecabtagene vicleucel and Secukinumab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Secukinumab is an IL-17A inhibitor that can raise infection risk, and CAR-T therapy already causes prolonged cytopenias and hypogammaglobulinemia. Combined use may add to infection susceptibility. Evidence is mostly theoretical.
What this interaction means in plain words
Idecabtagene vicleucel and Secukinumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Idecabtagene vicleucel belongs to Oncology; Secukinumab belongs to Miscellaneous.
Why it happens
Additive immunosuppression from IL-17A blockade and CAR-T related lymphodepletion and B-cell aplasia.
What to do
Avoid starting secukinumab around CAR-T infusion unless clearly needed; if used, monitor closely for infections and provide appropriate prophylaxis and immunoglobulin support per oncology protocols.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Idecabtagene vicleucel and Secukinumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Secukinumab
- Adenovirus types 4 and 7 live + Secukinumab Major
- Bcg vaccine live + Secukinumab Major
- Influenza virus vaccine quadrivalent intranasal + Secukinumab Major
- Measles mumps and rubella vaccine live + Secukinumab Major
- Measles mumps and rubella vaccine + Secukinumab Major
- Measles mumps rubella and varicella vaccine live + Secukinumab Major
Other interactions of Idecabtagene vicleucel
Frequently asked questions
Can I take Idecabtagene vicleucel with Secukinumab?
MediHelp rates the interaction as moderate. Idecabtagene vicleucel and Secukinumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Secukinumab is an IL-17A inhibitor that can raise infection risk, and CAR-T therapy already causes prolonged cytopenias and hypogammaglobulinemia. Combined use may add to infection susceptibility. Evidence is mostly theoretical.
How serious is the interaction between Idecabtagene vicleucel and Secukinumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid starting secukinumab around CAR-T infusion unless clearly needed; if used, monitor closely for infections and provide appropriate prophylaxis and immunoglobulin support per oncology protocols.
What other medicines interact with Secukinumab?
MediHelp also lists interactions of Secukinumab with, for example, Adenovirus types 4 and 7 live, Bcg vaccine live, Influenza virus vaccine quadrivalent intranasal. The full list is on the Secukinumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
